25% Discount on Whole Exome Sequencing Market by Product

Report Description

The applications of whole exome sequencing (WES) technologies have witnessed growth in recent years, which can be primarily attributed to the availability of advanced systems as well as the low cost of conducting exome sequencing, as compared with that of whole genome sequencing. The technological advancement is evident from the number of improved versions of existing sequencers released in recent years. For instance, in January 2014, the leading player in the whole exome sequencing market, Illumina, Inc. (U.S.), launched its NextSeq 500 System, which combines high-throughput performance with an affordable desktop form factor. This system is expected to enable researchers to perform sequencing in less than a day.

The major factors driving the growth of this market include its low cost and high speed, increase in applications areas for exome sequencing technologies, global alliances amongst leading research institutes to boost drug discovery, and the entry of new players in the whole-exome sequencing market. However, the high cost of instruments, the need for skilled professionals and high reliability on grants are hindering the market’s growth.

The services segment has the largest share of the global whole exome sequencing market, since it has a variety of applications in all areas, including diagnostics, drug discovery and development, personalized medicine, and agriculture and animal research. Diagnostics emerged as the largest whole exome sequencing application, primarily because of an increase in the usage of exome sequencing technologies in cancer and rare disease research.

In the years to come, the whole exome sequencing market is expected to experience high growth in Asia, particularly in China and India. These countries will serve as new revenue pockets for whole exome sequencing products and services companies. High growth in these regions can be attributed to growth in the pharmaceutical and biotech industry and crop research,...